Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) WILL PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE ON WEDNESDAY, SEPTEMBER 9TH, 2026. MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT 11:00 A.M. EASTERN TIME. A LIVE AUDIO WEBCAST OF THE PRESENTATION WILL BE ACCESSIBLE THROUGH JOHNSON & JOHNSON'S INVESTOR RELATIONS WEBSITE AT WWW.INVESTOR.JNJ.COM. AN ARCHIVED EDITION OF THE SESSION WILL BE AVAILABLE LATER THAT DAY. THE AUDIO WEBCAST REPLAY WILL BE AVAILABLE AP.

JOHNSON & JOHNSON TO PARTICIPATE IN THE 2026 WELLS FARGO HEALTHCARE CONFERENCE

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) TODAY ANNOUNCED THAT JENNIFER TAUBERT WILL RETIRE FROM HER POSITION AS EXECUTIVE VICE PRESIDENT, WORLDWIDE CHAIRMAN, INNOVATIVE MEDICINE FOLLOWING A DISTINGUISHED CAREER AND OVER 21-YEAR TENURE AT JOHNSON & JOHNSON. UNDER HER LEADERSHIP, THE COMPANY'S INNOVATIVE MEDICINE BUSINESS GREW TO MORE THAN $60 BILLION IN ANNUAL REVENUE AND STRENGTHENED ITS POSITION AS ONE OF THE MOST RESPECTED AND SUCCESSFUL PHARMACEUTICAL BUSIN.

JOHNSON & JOHNSON'S EXECUTIVE VICE PRESIDENT JENNIFER TAUBERT TO RETIRE; TOM CAVANAUGH APPOINTED EVP, WORLDWIDE CHAIRMAN INNOVATIVE MEDICINE EFFECTIVE SEPTEMBER

PRIORITY REVIEW REINFORCES THE SIGNIFICANT POTENTIAL OF SUBCUTANEOUS AMIVANTAMAB IN RECURRENT OR METASTATIC HEAD AND NECK CANCER, WHERE THE CURRENT FIVE-YEAR SURVIVAL RATE IS ONLY 15 PERCENT PATIENTS ACHIEVED RAPID, DEEP AND DURABLE RESPONSES, INCLUDING A 42 PERCENT OVERALL RESPONSE RATE WITH ONE-THIRD ACHIEVING A COMPLETE RESPONSE SUBCUTANEOUS AMIVANTAMAB IS THE ONLY THERAPY IN HEAD AND NECK CANCER ENGINEERED TO TARGET BOTH EGFR AND MET, PROVEN DRIVERS OF TUMOR GROWTH AND TREATMENT RESISTANCE RARITAN, N.J., JULY 30, 2026 /PRNEWSWIRE/ --JOHNSON & JOHNSON (NYSE:JNJ) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED PRIORITY REVIEW TO THE SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR SUBCUTANEOUS AMIVANTAMAB AND HYALURONIDASE-LPUJ FOR ADULTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC).

JOHNSON & JOHNSON'S RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ) RECEIVES U.S. FDA PRIORITY REVIEW AS POTENTIAL FIRST-IN-CLASS EGFR- AND MET-TARGETED SUBCUTANEOUS TREATMENT FOR ADVANCED HEAD AND NECK CANCER

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF ITS ACQUISITION OF FIREFLY BIO, INC., A BIOTECHNOLOGY COMPANY ADVANCING ITS PROPRIETARY FIRELINK DEGRADER ANTIBODY CONJUGATE (DAC) PLATFORM, FOR $1 BILLION IN CASH. THE FIRELINK DAC PLATFORM EXPANDS JOHNSON & JOHNSON'S ONCOLOGY PORTFOLIO AND ADVANCES ITS AMBITION TO DEVELOP TARGETED THERAPIES FOR SOME OF THE MOST PREVALENT AND DIFFICULT-TO-TREAT SOLID TUMORS, INCLUDING KRAS.

JOHNSON & JOHNSON COMPLETES ACQUISITION OF FIREFLY BIO, INC. TO ADVANCE NEXT-GENERATION ONCOLOGY INNOVATION

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON1 (NYSE: JNJ) TODAY ANNOUNCED STRATEGIC AGREEMENTS AND COLLABORATION WITH SAIL BIOMEDICINES (SAIL), A BIOTECHNOLOGY COMPANY DEVELOPING IN VIVO CAR-T THERAPIES FOR IMMUNE-MEDIATED DISEASES. JOHNSON & JOHNSON WILL COLLABORATE WITH SAIL TO ADVANCE ITS LEAD IMMUNE-MEDIATED DISEASE PROGRAM AND BROADER PLATFORM TECHNOLOGY, WITH INCENTIVES TO EXPAND THE APPLICATION OF SAIL'S IN VIVO CAR-T PLATFORM ACROSS ADDITIONAL THERAPEUTIC TARGETS OVER.

JOHNSON & JOHNSON ANNOUNCES COLLABORATION WITH SAIL BIOMEDICINES TO ADVANCE IN VIVO CAR-T PROGRAMS AND TRANSFORM AUTOIMMUNE DISEASE THROUGH IMMUNE RESET

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) (THE "COMPANY") TODAY ANNOUNCED THAT IT HAS REACHED AN AGREEMENT FOR A COMPREHENSIVE RESOLUTION OF THE REMAINING TALC LITIGATION WITH THE PLAINTIFF FIRMS LEADING THE FEDERAL MULTI-DISTRICT LITIGATION (MDL) AND RELATED STATE COURT PROCEEDINGS, CONDITIONED ON, AMONG OTHER THINGS, THE EXPRESS PARTICIPATION OF AT LEAST 95% OF THE REMAINING CLAIMS. THE PROPOSED RESOLUTION FOLLOWS A FAVORABLE RULING BY THE MDL COURT, AND ACKNOWLE.

JOHNSON & JOHNSON ANNOUNCES A PROPOSED RESOLUTION OF OVARIAN TALC LITIGATION

INVESTIGATIONAL MONUMENTAL-6 TRIAL IS THE FIRST AND ONLY PHASE 3 STUDY OF A DUAL ANTIGEN, BCMA AND GPRC5D TARGETING REGIMEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA FIFTH POSITIVE PHASE 3 STUDY EVALUATING JOHNSON & JOHNSON'S MULTIPLE MYELOMA T-CELL THERAPY PORTFOLIO IN SECOND LINE, FURTHER STRENGTHENING THE COMPANY'S LEADERSHIP AND COMMITMENT TO ADVANCING IMMUNOTHERAPY-BASED REGIMENS EARLIER IN THE TREATMENT JOURNEY RARITAN, N.J., JULY 23, 2026 /PRNEWSWIRE/ -- JOHNSON & JOHNSON (NYSE:JNJ), A WORLDWIDE LEADER IN MULTIPLE MYELOMA THERAPIES, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE THREE-ARM INVESTIGATIONAL PHASE 3 MONUMENTAL-6 STUDY EVALUATING TECVAYLI (TECLISTAMAB-CQYV) + TALVEY (TALQUETAMAB-TGVS), A BCMA AND GPRC5D DUAL ANTIGEN TARGETING REGIMEN, AND TALVEY + POMALIDOMIDE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVED 1 TO 4 PRIOR LINES OF THERAPY, INCLUDING AN ANTI-CD38 ANTIBODY AND LENALIDOMIDE.1 THE STUDY DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FOR BOTH INVESTIGATIONAL ARMS COMPARED WITH INVESTIGATOR'S CHOICE STANDARD OF CARE.

TECVAYLI + TALVEY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 89% AND THE RISK OF DEATH BY 62% IN EARLIER-LINE RELAPSED/REFRACTORY MULTIPLE MYELOMA

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED DE NOVO AUTHORIZATION FOR THE OTTAVA ROBOTIC SURGICAL SYSTEM, THE WORLD'S FIRST TABLE-INTEGRATED SOFT TISSUE ROBOTIC SYSTEM. THE SYSTEM RECEIVED MARKETING AUTHORIZATION FOR MULTIPLE PROCEDURES IN GENERAL SURGERY, INCLUDING ROUX-EN-Y GASTRIC BYPASS, GASTRECTOMY, CHOLECYSTECTOMY, SPLENECTOMY, GASTRIC SLEEVE, SMALL BOWEL RESECTION, APPENDECTOMY, LYSIS OF ADHESIO.

JOHNSON & JOHNSON RECEIVES FDA MARKET AUTHORIZATION IN THE U.S. FOR ITS OTTAVA ROBOTIC SURGICAL SYSTEM

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) TODAY ANNOUNCED WITH TIME THE LAUNCH OF THE HEALTHCARE CHAMPION OF THE YEAR. THE NEW BRANDED RECOGNITION WILL HONOR HEALTHCARE PROFESSIONALS IN THE U.S., SELECTED BY JOHNSON & JOHNSON AND A PANEL OF INDUSTRY EXPERTS, WHOSE CARE, INNOVATION AND GRIT ARE DRIVING HEALTH SYSTEM CHANGE TO ADVANCE BETTER CARE FOR ALL. NOMINATIONS FOR THE INAUGURAL TIME HEALTHCARE CHAMPION OF THE YEAR, IN PARTNERSHIP WITH JOHNSON & JOHNSON.

JOHNSON & JOHNSON ANNOUNCES COLLABORATION WITH TIME TO INTRODUCE NEW HEALTHCARE CHAMPION OF THE YEAR AWARD

RAYNHAM, MASS.--(BUSINESS WIRE)--DEPUY SYNTHES, A GLOBAL LEADER IN ORTHOPAEDIC TECHNOLOGIES AND SOLUTIONS, TODAY ANNOUNCED IT HAS ACQUIRED EXPANDING INNOVATIONS, INC., AN EMERGING LEADER IN EXPANDABLE IMPLANT TECHNOLOGY FOR SPINE SURGERY. THE TRANSACTION STRENGTHENS DEPUY SYNTHES' SPINE PORTFOLIO AND EXPANDS ITS POSITION IN THE RAPIDLY GROWING EXPANDABLE INTERBODY CAGE SEGMENT. EXPANDING INNOVATIONS (EI) IS A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING.

DEPUY SYNTHES ACQUIRES EXPANDING INNOVATIONS

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DECLARED A CASH DIVIDEND FOR THE THIRD QUARTER OF 2026 OF $1.34 PER SHARE ON THE COMPANY'S COMMON STOCK. THE DIVIDEND IS PAYABLE ON SEPTEMBER 8, 2026 TO SHAREHOLDERS OF RECORD AT THE CLOSE OF BUSINESS ON AUGUST 25, 2026. THE EX-DIVIDEND DATE IS AUGUST 25, 2026. ABOUT JOHNSON & JOHNSON AT JOHNSON & JOHNSON, WE BELIEVE HEALTH IS EVERYTHING. OUR STRENGTH IN HEALTHCARE INN.

JOHNSON & JOHNSON ANNOUNCES QUARTERLY DIVIDEND FOR THIRD QUARTER 2026

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) TODAY ANNOUNCED RESULTS FOR SECOND-QUARTER 2026. JOHNSON & JOHNSON DELIVERED STRONG SECOND-QUARTER RESULTS, DEMONSTRATING THE POWER OF OUR INNOVATION, THE DEPTH OF OUR PORTFOLIO AND THE MOMENTUM IN OUR PIPELINE AS WE ADVANCE TRANSFORMATIVE TREATMENTS THAT ADDRESS THE WORLD'S TOUGHEST HEALTH CHALLENGES, SAID JOAQUIN DUATO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, JOHNSON & JOHNSON. WITH RAISED GUIDANCE AND QUARTERLY.

JOHNSON & JOHNSON REPORTS Q2 2026 RESULTS, RAISES 2026 OUTLOOK

IRVINE, CALIF.--(BUSINESS WIRE)--JOHNSON & JOHNSON ANNOUNCES FDA APPROVAL FOR THE DUAL ENERGY THERMOCOOL SMARTTOUCH SF PLATFORM.

JOHNSON & JOHNSON ANNOUNCES FDA APPROVAL FOR THE DUAL ENERGY THERMOCOOL SMARTTOUCH SF PLATFORM

NEW ANALYSES FROM THE PHASE 3 VIVACITY-MG3 STUDY SUPPORT THE IMPACT OF IMAAVY IN ANTI-ACHR+ A , ANTI-MUSK+B ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG) INCLUDING THOSE EARLY IN THEIR DISEASE, PARTICIPANTS WITH LOWER SYMPTOM BURDEN AND THOSE WHO EXPERIENCED COMMON INFECTIONS TO ADDRESS AN IMPORTANT EVIDENCE GAP, THE PETUNIAC STUDY DESIGN WILL BE PRESENTED  DEMONSTRATING THE INNOVATIVE WAY PREGNANCY OUTCOMES DATA WILL BE COLLECTED FOLLOWING TREATMENT WITH IMAAVY IMAAVY, AN IMMUNOSELECTIVE NEONATAL FC RECEPTOR (FCRN) BLOCKER, IS DESIGNED TO TARGET AND REDUCE PATHOGENIC IMMUNOGLOBULIN G (IGG) AUTOANTIBODIES ASSOCIATED WITH GENERALIZED MYASTHENIA GRAVIS (GMG) GENEVA, JUNE 26, 2026 /PRNEWSWIRE/ -- JOHNSON & JOHNSON (NYSE: JNJ) TODAY ANNOUNCED NEW DATA ACROSS 12 ABSTRACTS AT THE EUROPEAN ACADEMY OF NEUROLOGY (EAN) 2026 CONGRESS THAT OFFER ADDITIONAL INSIGHT INTO THE USE OF IMAAVY (NIPOCALIMAB-AAHU) THROUGHOUT CLINICALLY RELEVANT POINTS IN THE GENERALIZED MYASTHENIA GRAVIS (GMG) TREATMENT JOURNEY. THE ANALYSES INCLUDE ADULTS WITH ANTI-ACHRA OR ANTI-MUSKB ANTIBODY-POSITIVE GMG WHO WERE EARLY IN THEIR DISEASE COURSE OR HAD LOWER BASELINE SYMPTOM BURDEN  PROVIDING INSIGHT INTO THE POTENTIAL IMPORTANCE OF ADDRESSING PATHOGENIC IMMUNOGLOBULIN G (IGG) EARLY IN DISEASE PROGRESSION WHERE USE OF ADVANCED THERAPIES MAY BE LESS COMMON.1 , 2ADDITIONAL RESEARCH TO BE SHARED INCLUDE OUTCOMES SHORTLY AFTER COMMON INFECTIONS, WHICH ARE A KNOWN CAUSE OF DISEASE EXACERBATIONS IN GMG, AND PLANS TO ADDRESS EVIDENCE GAPS IN USE OF IMAAVY DURING PREGNANCY.3 , 4 "FOR MANY PEOPLE LIVING WITH GENERALIZED MYASTHENIA GRAVIS, ACHIEVING AND MAINTAINING SUSTAINED DISEASE CONTROL IS AN IMPORTANT GOAL THROUGHOUT THE COURSE OF THEIR DISEASE, FROM THE MOMENT THEY ARE DIAGNOSED AND ACROSS THE DIFFERENT STAGES OF THEIR JOURNEY," SAID CARLO ANTOZZI, M.D.

JOHNSON & JOHNSON PRESENTS NEW IMAAVY (NIPOCALIMAB-AAHU) DATA AT EUROPEAN ACADEMY OF NEUROLOGY (EAN) 2026 CONGRESS REINFORCING SUSTAINED DISEASE CONTROL IN GENERALIZED MYASTHENIA GRAVIS

IRVINE, CALIF.--(BUSINESS WIRE)--JOHNSON & JOHNSON ADVANCES CARDIAC ABLATION TECHNOLOGY IN EUROPE WITH AVAILABILITY OF DUAL ENERGY THERMOCOOL SMARTTOUCH SF PLATFORM.

JOHNSON & JOHNSON ADVANCES CARDIAC ABLATION TECHNOLOGY IN EUROPE WITH AVAILABILITY OF DUAL ENERGY THERMOCOOL SMARTTOUCH SF PLATFORM

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) (THE COMPANY), HEALTHCARE'S LEADING, MOST COMPREHENSIVE INNOVATION POWERHOUSE, TODAY ANNOUNCED AN INVESTMENT OF MORE THAN $1 BILLION IN JACKSONVILLE, FLORIDA TO STRENGTHEN ITS VISION OPERATIONS BY SCALING U.S.-BASED MANUFACTURING, PACKAGING AND DISTRIBUTION CAPABILITIES. THE INVESTMENT INCLUDES CONSTRUCTION OF A NEW, STATE-OF-THE-ART DISTRIBUTION FACILITY, ALONGSIDE ADVANCED MANUFACTURING AND PACKAGING TECHNOLOGIES TO EXP.

JOHNSON & JOHNSON INVESTS MORE THAN $1 BILLION TO STRENGTHEN U.S. VISION MANUFACTURING IN JACKSONVILLE, FLORIDA

BEERSE, BELGIUM, JUNE 13, 2026 (GLOBE NEWSWIRE) -- JOHNSON & JOHNSON TODAY ANNOUNCED RESULTS FROM THE INVESTIGATIONAL PHASE 3 MONUMENTAL-3 STUDY.1 THE RESULTS SHOWED THAT TALVEY (TALQUETAMAB), A GPRC5D BISPECIFIC ANTIBODY, IN COMBINATION WITH DARATUMUMAB WITH OR WITHOUT POMALIDOMIDE DEMONSTRATED SIGNIFICANT REDUCTION IN THE RISK OF DISEASE PROGRESSION OR DEATH OF UP TO 72.0%, AND CLINICALLY MEANINGFUL REDUCTION OF UP TO 53.0% IN THE RISK OF DEATH, COMPARED TO THE STANDARD REGIMEN OF DARATUMUMAB, POMALIDOMIDE, AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM).1 RESULTS SHOWED A PROGRESSION-FREE SURVIVAL (PFS) RATE OF UP TO 81.3% VERSUS STANDARD OF CARE (51.2%) AND AN OVERALL SURVIVAL (OS) RATE OF UP TO 89.2% VERSUS STANDARD OF CARE (79.1%) AT 24 MONTHS.

NEW TALVEY(TALQUETAMAB) PLUS DARATUMUMAB DATA DEMONSTRATE THE POTENTIAL STRENGTH OF A NOVEL BISPECIFIC COMBINATION IN EARLIER-LINE RELAPSED OR REFRACTORY MULTIPLE MYELOMA

TALVEY PLUS DARZALEX FASPRO WITH OR WITHOUT POMALIDOMIDE SHOWED PROGRESSION-FREE SURVIVAL OF UP TO 81% AND OVERALL SURVIVAL OF UP TO 89% AT 24 MONTHS

NEW TALVEY (TALQUETAMAB-TGVS) PLUS DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) DATA DEMONSTRATE THE STRENGTH OF A BISPECIFIC COMBINATION IN EARLIER-LINE RELAPSED OR REFRACTORY MULTIPLE MYELOMA

JACKSONVILLE, FLA.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) IS EXPANDING THE U.S. ROLL-OUT OF ITS LATEST ADVANCEMENT IN PRESBYOPIA-CORRECTING INTRAOCULAR LENSES (PC-IOLS). TECNIS PURESEE IOL IS AN EXTENDED DEPTH OF FOCUS (EDOF) LENS DESIGNED TO SUPPORT VISUAL CLARITY AND QUALITY FOR PATIENTS UNDERGOING CATARACT SURGERY.3 BENEFITS OF TECNIS PURESEE IOL: RANGE OF VISION: EXCELLENT DISTANCE AND INTERMEDIATE VISION WITH SOME NEAR VISION3* LOW LEVEL OF BOTHERSOME VISUAL SYMPTOMS: 97% OF P.

JOHNSON & JOHNSON EXPANDS U.S. AVAILABILITY OF TECNIS PURESEE IOL, AN ADVANCED LENS OPTION FOR CATARACT SURGEONS AND PATIENTS

PATIENTS IN THE IMAAVY 30 MG/KG TREATMENT GROUP A ACHIEVED STATISTICALLY SIGNIFICANT DURABLE HEMOGLOBIN RESPONSE B , WITH MEAN HEMOGLOBIN IMPROVEMENT OF AT LEAST 1 G/DL AS EARLY AS WEEK 1 C  MORE PATIENTS TREATED WITH IMAAVY EXPERIENCED IMPROVEMENT IN FATIGUE D AND CORTICOSTEROID DOSE REDUCTIONS E IMAAVY IS DESIGNED TO TARGET PATHOGENIC IMMUNOGLOBULIN G (IGG) AUTOANTIBODIES INWARM AUTOIMMUNE HEMOLYTIC ANEMIA WHILE PRESERVING IMMUNE FUNCTION PIVOTAL RESULTS WILL BE PRESENTED ATEHA 2026 STOCKHOLM, JUNE 11, 2026 /PRNEWSWIRE/ -- JOHNSON & JOHNSON (NYSE: JNJ) TODAY IS PRESENTING THE FIRST COMPREHENSIVE RESULTS FROM THE PHASE 2/3 ENERGY STUDY SHOWING THAT IMAAVY (NIPOCALIMAB-AAHU)PRODUCEDA STATISTICALLY SIGNIFICANT DURABLE HEMOGLOBIN(HGB)RESPONSEBWITH RAPID ONSET OF EFFECT IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA)E IN THE30 MG/KGTREATMENTGROUP,A COMPARED WITHTHOSEWHO RECEIVEDPLACEBO. THE RANDOMIZED, PLACEBO-CONTROLLED TRIAL DEMONSTRATED APPROXIMATELY THREE TIMES AS MANY PATIENTS ACHIEVED DURABLE HGB LEVELS VERSUS PLACEBO BY24 WEEKS.

IMAAVY (NIPOCALIMAB-AAHU) DEMONSTRATES DURABLE HEMOGLOBIN RESPONSE AND RAPID ONSET OF EFFECT IN PIVOTAL PHASE 2/3 STUDY IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA), AN AUTOANTIBODY-DRIVEN DISEASE WITH NO FDA-APPROVED THERAPIES

LOS ANGELES--(BUSINESS WIRE)-- #JOHNSONJOHNSON--A LOS ANGELES JURY HAS AWARDED $32 MILLION TO THE FAMILY OF A CALIFORNIA WOMAN WHO DIED FROM PLEURAL MESOTHELIOMA AFTER YEARS OF EXPOSURE TO AN ASBESTOS-CONTAMINATED TALC PRODUCT, FINDING JOHNSON & JOHNSON (NYSE: JNJ) AND ITS SUBSIDIARIES LIABLE FOR HER ILLNESS. MARIA LOZANO DIED FROM MESOTHELIOMA IN 2024. HER CHILDREN, JOHN LOZANO, ARACELI LENARD-LOZANO AND JEANETTE LOZANO, CONTINUED THE LAWSUIT AFTER HER DEATH. VIEW THE VERDICT FORM AND PHOTOS HERE. DURING TH.

JOHNSON & JOHNSON HIT WITH $32 MILLION VERDICT IN LOS ANGELES ASBESTOS TRIAL

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--JOHNSON & JOHNSON (NYSE: JNJ) TODAY ANNOUNCED IT HAS ENTERED INTO A DEFINITIVE AGREEMENT TO ACQUIRE FIREFLY BIO, INC., A BIOTECHNOLOGY COMPANY ADVANCING ITS PROPRIETARY FIRELINK DEGRADER ANTIBODY CONJUGATE (DAC) PLATFORM, FOR $1 BILLION IN CASH. THE FIRELINK DAC PLATFORM FOR KRAS-DRIVEN TUMORS BOLSTERS JOHNSON & JOHNSON'S ONCOLOGY PIPELINE AND AMBITION TO DEVELOP TARGETED MEDICINES FOR THE MOST PREVALENT AND HARD-TO-TREAT SOLID TUMORS WITH HIGH UN.

JOHNSON & JOHNSON TO ACQUIRE FIREFLY BIO, INC. TO EXPAND ONCOLOGY PIPELINE WITH NOVEL DEGRADER ANTIBODY CONJUGATE PLATFORM

FINANCING LED BY PIPER SANDLER MERCHANT BANKING, WITH PARTICIPATION FROM NEW INVESTORS JOHNSON & JOHNSON INNOVATION  JJDC, INC., JOHNSON & JOHNSON'S CORPORATE VENTURE CAPITAL ARM, AND MEDTRONIC PARTICIPATION BY EXISTING INVESTORS, INCLUDING BAIN CAPITAL LIFE SCIENCES AND PERCEPTIVE XONTOGENY VENTURE FUNDS PROCEEDS WILL SUPPORT THE CONCLUSION OF THE STRIDE PIVOTAL TRIAL, CONTINUED OPERATIONAL SCALE-UP, ADVANCEMENT OF REGULATORY WORK TOWARD A FUTURE PREMARKET APPROVAL (PMA) SUBMISSION TO THE FDA, AND PREPARATIONS FOR US COMMERCIALIZATION BOARD STRENGTHENED WITH ADDITION OF KEVIN CONROY AS LEAD INDEPENDENT DIRECTOR, CHRISTOPHER GEYEN AS CHAIR OF THE AUDIT COMMITTEE, AND TOM SCHNETTLER REPRESENTING SERIES C INVESTORS BOSTON, JUNE 4, 2026 /PRNEWSWIRE/ -- CEREVASC, INC., A CLINICAL-STAGE MEDICAL DEVICE COMPANY DEVELOPING NOVEL, MINIMALLY INVASIVE TREATMENTS FOR NEUROLOGICAL DISEASES, TODAY ANNOUNCED IT HAS SUCCESSFULLY COMPLETED THE INITIAL CLOSING OF AN $85 MILLION SERIES C FINANCING. PIPER SANDLER MERCHANT BANKING LED THE FINANCING WITH PARTICIPATION FROM JOHNSON & JOHNSON INNOVATION  JJDC, INC., JOHNSON & JOHNSON'S CORPORATE VENTURE CAPITAL ARM, AND MEDTRONIC, ALONG WITH EXISTING INVESTORS BAIN CAPITAL LIFE SCIENCES AND PERCEPTIVE XONTOGENY VENTURE FUNDS.

CEREVASC, INC. ANNOUNCES OVER-SUBSCRIBED $85 MILLION SERIES C FINANCING TO ADVANCE ITS NOVEL ESHUNT SYSTEM FOR THE TREATMENT OF NORMAL PRESSURE HYDROCEPHALUS

NIPOCALIMAB  THE FIRST AND ONLY NEONATAL FC RECEPTOR (FCRN) BLOCKER TO BE STUDIED IN SYSTEMIC LUPUS ERYTHEMATOSUS  IS DESIGNED TO TARGET AND REDUCE PATHOGENIC IMMUNOGLOBULIN G (IGG) AUTOANTIBODIES ASSOCIATED WITH THIS DISEASE WHILE PRESERVING IMMUNE FUNCTION RESULTS DEMONSTRATED SIGNIFICANT REDUCTION OF SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY WHICH CONTINUED BEYOND THE 24-WEEK PRIMARY ENDPOINT, AND WERE SUSTAINED THROUGH WEEK 52 IN THE NIPOCALIMAB 15 MG/KG GROUPA THE ONGOING PHASE 3 STUDY OF NIPOCALIMAB IS CURRENTLY RECRUITING PEOPLE LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS  A DEBILITATING AUTOANTIBODY-DRIVEN DISEASE WHICH CAN LEAD TO SYSTEMIC ORGAN DAMAGE LONDON, JUNE 3, 2026 /PRNEWSWIRE/ -- JOHNSON & JOHNSON (NYSE: JNJ) TODAY ANNOUNCEDNIPOCALIMAB MET THE PRIMARY ENDPOINT OF DECREASING DISEASE ACTIVITY AT 24 WEEKS AS MEASURED BY SLE RESPONDER INDEX 4 (SRI-4)B AND CONTINUED TO DEMONSTRATE SUSTAINED REDUCTION IN DISEASE ACTIVITY IN ADULTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)A THROUGH 52 WEEKS IN THE PHASE 2 JASMINE STUDY AS MEASURED BY BOTH SRI-4B AND LUPUS LOW DISEASE ACTIVITY STATE (LLDAS).C IN ADDITION, THE STUDY RESULTS SHOWED GREATER RESPONSE VERSUS PLACEBO PLUS BACKGROUND MEDICATIOND IN PARTICIPANTS WHO TESTED POSITIVE FOR LUPUS-ASSOCIATED AUTOANTIBODIES, WHICH REPRESENTS THE VAST MAJORITY (~80%) OF PEOPLE LIVING WITH SLE.E,1 THESE FINDINGS WILL BE FEATURED IN A LATE-BREAKING PRESENTATION AT THE EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY (EULAR) 2026CONGRESSIN LONDON AND ARE AMONGTHE38 ABSTRACTSTHE COMPANY IS PRESENTING ACROSS ITS RHEUMATOLOGY PORTFOLIO. NIPOCALIMAB IS DESIGNED TO SELECTIVELY BLOCK THE NEONATAL FC RECEPTOR (FCRN), REDUCING LEVELS OF CIRCULATING PATHOGENIC IMMUNOGLOBULIN (IGG) AUTOANTIBODIES AND IMMUNE COMPLEXES ASSOCIATED WITH INFLAMMATION IN SLE.2,3 BY REDUCING CIRCULATING IGG, INCLUDING AUTOANTIBODIES, NIPOCALIMAB IS DESIGNED TO TARGET THE UNDERLYING CAUSE OF DISEASE WHILE PRESERVING CRITICAL IMMUNE FUNCTIO

JOHNSON & JOHNSON LATE-BREAKING RESULTS SHOW NIPOCALIMAB SIGNIFICANTLY REDUCED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY IN A PHASE 2 STUDY

NIPOCALIMAB, AN IMMUNOSELECTIVE NEONATAL FC RECEPTOR (FCRN) BLOCKER, IS DESIGNED TO TARGET AND REDUCE PATHOGENIC IMMUNOGLOBULIN G (IGG) AUTOANTIBODIES ASSOCIATED WITH SJGREN'S DISEASE WHILE PRESERVING IMMUNE FUNCTION NEW EXPLORATORY ANALYSIS OF PHASE 2 STUDY DATA SHOWS A STRONG CORRELATION BETWEEN AUTOANTIBODY LEVELS AND EVEN GREATER CLINICAL RESPONSE RATES OF PARTICIPANTS IN THE NIPOCALIMAB TREATMENT GROUP PREVIOUSLY REPORTED DATA FROM THE PHASE 2 STUDY SHOWED NIPOCALIMAB REDUCED SJGREN'S DISEASE ACTIVITY AND SEVERITY, WITH POTENTIAL TO ADDRESS SYSTEMIC MANIFESTATIONS AND THE MOST BURDENSOME PATIENT-REPORTED SYMPTOMS INCLUDING DRYNESS, FATIGUE AND PAIN NIPOCALIMAB IS THE ONLY FCRN BLOCKER GRANTED BOTH BREAKTHROUGH THERAPY DESIGNATION AND FAST TRACK DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE SJGREN'S DISEASE. LONDON, JUNE 3, 2026 /PRNEWSWIRE/ -- JOHNSON & JOHNSON (NYSE: JNJ) TODAY ANNOUNCEDNEW BIOMARKER EXPLORATORY ANALYSES FROM THE PHASE 2DAHLIASSTUDY EVALUATINGNIPOCALIMABIN ADULTS WITH MODERATE-TO-SEVERE SJGREN'S DISEASE (SJD)A SHOWING THAT PARTICIPANTS WITH ELEVATED AUTOANTIBODY AND IMMUNOGLOBULIN G (IGG) LEVELSB, WHO ARE OFTEN THOSE WHO EXPERIENCE MORE SUBSTANTIAL DISEASE BURDEN, SHOWED GREATER CLINICAL RESPONSE RATES.1 THESE DATA WILL BE PRESENTED IN AN ORAL SESSION AT THE 2026 EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY (EULAR) CONGRESS.

Johnson & Johnson

JNJ

Price

Financial Reports

No items found.

Press Releases

Johnson & Johnson

JNJ.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

JNJ